Quick Dispatch:
Your surpass trial tirzepatide Full article: An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surpass trial tirzepatide Full article: An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program ships.
Need Help?
Questions about surpass trial tirzepatide Full article: An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surpass trial tirzepatide Full article: An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program in your area.
SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes
23.56
01443-4/asset/63fe4912-d57e-4c87-ad6b-1952000f93e1/main.assets/gr1_lrg.jpg "Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial")
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
22.52
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity
26.55
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice
28.42
Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial
28.23
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
28.40
Effects of tirzepatide on adjudicated cardiovascular events in
20.87
